TITLE:
Teneligliptin: Heralding Change in Type 2 Diabetes
AUTHORS:
Manish Maladkar, Srividya Sankar, Kushal Kamat
KEYWORDS:
Teneligliptin, DPP-4 Inhibitors, GLP-1, β-Cell Preservation, Pleiotropic Benefits, Gliptins
JOURNAL NAME:
Journal of Diabetes Mellitus,
Vol.6 No.2,
March
31,
2016
ABSTRACT: “Sweet is Sweet but until it is not too Sweet”. As the sweet spoon of
diabetes challenges the global population, diabetic organizations across the
globe call for unanimous resonance of Diabetes
Voice to tackle diabetes with healthy living. With the discovery of new
pathophysiology associated with diabetes, patients are gaining access to the newer
therapeutic classes. Teneligliptin, a third generation DPP-4 inhibitor exhibits
unique “J-shaped” structure with “anchor-lock domain” mechanism which provides
potent & long duration of action. It acts like an insulin/glucagon
modulator controlling blood glucose over 24 hours. It is effective in tackling
short-term glycemic fluctuations and improvement in β-cell parameters is observed soon after treatment. Half-life of
26.9 hours ensures once a day administration. Because the metabolites of this
drug are eliminated via renal and hepatic excretion, no dose adjustment is
necessary in patients with renal impairment. Improvement in lipid profile, LV
function, adiponectin levels & natriuretic effect is among the added pleiotropic
benefits. With the effective glycemic control & capability for improvement
in β-cell function, Teneligliptin
promises to be a preferable antidiabetic agent with long-term efficacy &
safety in patients with type 2 diabetes. The objective of this paper is to
provide a comprehensive datum analysis of Teneligliptin in the management of
type 2 diabetes. It summarizes the unique pharmacodynamic & pharmacokinetic
advantages of Teneligliptin and additionally its pleiotropic benefits of
cardioprotection. It provides a comprehensive comparison of Teneligliptin
vis-à-vis other gliptins in the class & provides a concise summary of all
clinical trials till the date with Teneligliptin monotherapy & combination
with other antidiabetic drugs.